Summary:
The hepatitis C virus (HCV) infection may change the outcome of patients undergoing stem cell transplantation. This study aimed at determining the prevalence of the HCV antibody in patients who were alive 10 or more years after BMT, defining the annual progression rate of hepatic fibrosis in those patients, and identifying cases of cirrhosis among those who were positive for HCV antibody. Between 1979 and 1990, 259 patients had a bone marrow transplant, and 91 were alive in March 2000. Of those, 80 were included in the study after having been scanned for serum HCV antibodies. A total of 39 were positive (48.8%), one was indeterminate and 40 were negative (50%). The patients who were HCV positive or undetermined were called for a medical appointment and 22 (55%) attended. A total of 16 patients (72.7%) were male, the mean age was 37.8±9.2 years and all of them had had an allogeneic transplant. Of the 22 patients studied, 12 (54.5%) agreed to have a liver biopsy. Hepatic fibrosis was diagnosed in 10 patients. The hepatic fibrosis annual progression rate was 0.156 UF/year. Among the anti-HCV-positive patients assessed, three (13.6%) already had cirrhosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Choo QL, Kuo G, Weiner AJ et al. Isolation of a DNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359–362.
Brazil. Ministry of Health. Administrative Rule no. 1376, of November 19, 1993. Diário Oficial, Brasília, 1993; pp 18405–18415.
Strasser SI, McDonald GB . Gastrointestinal and hepatic complications. In: Thomas ED, Blume KG, Forman SJ (eds.). Hematopoietic Cell Transplantation. Blackwell Scientific Publications: Cambridge, 1999; pp 627–658.
Strasser SI, Myerson D, Spurgeon CL et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999; 29: 1893–1899.
Locasciulli A, Bacigalupo A, Vanlint MT et al. Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16: 407–411.
Ljungman P, Johansson N, Aschan J et al. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood 1995; 86: 1614–1618.
Akiyama H, Yoshinaga H, Tanaka T et al. Effects of cyclosporin A on hepatitis C virus infection in bone marrow transplant patients. Bone Marrow Transplant 1997; 20: 993–995.
Poynard T . Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825–832.
Stanton AG . Primer of Biostatistics: Version 4.0, 4 edn. McGraw Hill: New York, 1997.
Kolho E, Ruutu P, Ruutu T . Hepatitis C infection in BMT patients. Bone Marrow Transplant 1993; 11: 119–123.
Locasciulli A, Bacigalupo A, Vanlint MT et al. Hepatitis C virus infection in patients undergoing allogeneic bone marrow transplantation. Transplantation 1991; 52: 315–318.
Locasciulli A, Nava S, Sparano P, Testa M . Infections with hepatotropic viruses in children treated with allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21 (Suppl.): 575–577.
Locasciulli A, Alberti A, de Bock R et al. Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: a survey from the European bone marrow transplantation group infectious diseases working party. Bone Marrow Transplant 1994; 14: 833–837.
Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556–562.
Silva AO et al. Dimensões epidêmicas da infecção causada pelo vírus da hepatite C. (Epidemics of infection by hepatitis-C virus). In: Silva AO (ed.). Hepatite Viral C. Pizarro Farmacêutica: São Paulo, 2001; pp 27–35.
Heintges T, Wands JR . Hepatitis C virus: epidemiology and transmission. Hepatology 1997; 26: 521–526.
Cornu C, Brusselmans C, Geubel A et al. Anti-HCV seroconversion in multitransfused and immunocompromised patients. Vox Sanguinis: Int J Blood Transf Immunohaematol 1994; 67: 286–290.
Tada K, Tajiri H, Kozaiwa K et al. Role of screening for hepatitis C virus in children with malignant disease and who undergo bone marrow transplantation. Transfusion 1997; 37: 641–644.
Lok AS, Chien D, Choo QL et al. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosupressed patients. Hepatology 1993; 18: 497–502.
Locasciulli A, Testa M, Valsecchi MG et al. The role of hepatitis C and B virus infection as risk factors for severe liver complications following allogeneic BMT: a prospective study by the infectious disease working party of the European blood and marrow transplantation group. Transplantation 1999; 68: 1486–1491.
Strasser S, Sullivan KM, Myerson D et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood 1999; 93: 3259–3266.
Maruta A, Kanamori H, Fukawa H et al. Liver function texts of recipients with hepatitis virus infection after bone marrow transplantation. Bone Marrow Transplant 1994; 13: 417–422.
Tomas JF, Pinilla I, Gracia-Bucy ML et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients. Bone Marrow Transplant 2000; 26: 649–655.
Norol F, Nadjahi J, Bachir D et al. Hepatitis C virus infection and allogeneic bone marrow transplantation. Transplantation 1994; 57: 393–397.
Mckay PJ, Murphy JA, Cameron S et al. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant 1996; 17: 63–66.
Strasser S, McDonald G . Viruses and hematopoietic cell transplantation: a guide to patient and donor management. Blood 1999; 93: 1127–1136.
Ivantes CAP, Amarante H, Ioshii S, Pasquini R . Treatment of chronic hepatitis C in bone marrow transplant recipients. 2004; (submitted for publication).
Acknowledgements
Dr George McDonald, Fred Hutchinson Cancer Research Center, Seattle; Dr Eliane Ribeiro Carmes, Curitiba; Dr Maria Lúcia Pedroso, HC-UFPR, Curitiba; Sueli Nakatani, Coordinator of the Molecular Biology Sector of LACEN, Curitiba; Dr Margaret Ono, Head of the Serology Lab of HC-UFPR, Curitiba; Dr Noemi Farah Pereira, Head of the Immunogenetics Lab of the HC-UFPR, Curitiba; and Roche Diagnostics for the financial support for carrying out the project.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ivantes, C., Amarante, H., Ioshii, S. et al. Hepatitis C virus in long-term bone marrow transplant survivors. Bone Marrow Transplant 33, 1181–1185 (2004). https://doi.org/10.1038/sj.bmt.1704519
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704519
Keywords
This article is cited by
-
Treatment of hepatitis C in a pediatric patient using simeprevir and sofosbuvir immediately after an umbilical cord blood transplantation
Bone Marrow Transplantation (2016)
-
Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact
Journal of Translational Medicine (2012)
-
Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy
Bone Marrow Transplantation (2012)
-
Abnormal liver enzymes 2 years after haematopoietic stem cell transplantation in children: prevalence and risk factors
Bone Marrow Transplantation (2008)
-
Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients
Bone Marrow Transplantation (2005)